Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs

Circulation Research

Volumn 78, Issue 1, 1996, Pages 154-160

  Murray, David R ^a   Freeman, Gregory L ^b  

^a Medicine/Cardiology   (United States)

^b NONE

Author keywords

cytokine; epinephrine; left ventricular function; norepinephrine; septic shock

Indexed keywords

ADRENALIN; ATROPINE; NORADRENALIN; PROPRANOLOL; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADRENALIN BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOG; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE CONTRACTILITY; INOTROPISM; MUSCLE TONE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEPTIC SHOCK; SYMPATHETIC TONE;

EID: 0030024564     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.78.1.154     Document Type: Article

References (45)

1. Beutler B, Cerami A. The biology of cachectin/TNF-α: a primary mediator of the host response. Annu Rev Immunol. 1989;7:625-655.
2. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987;47:2986-2989.
3. Natanson CP, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989; 169:823-832.
4. Tracey KJ, Lowry SF, Fahey TJ III, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164:415-422.
5. Kreil EA, Greene E, Fitzgibbon C, Robinson DR, Zapol WM. Effects of recombinant human tumor necrosis factor alpha, lymphotoxin, and Escherichia coli lipopolysaccharide on hemodynamics, lung microvascular permeability, and eicosanoid synthesis in anesthetized sheep. Circ Res. 1989;65:502-514.
6. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature. 1987;330: 662-664.
7. Zingarelli B, Squadrito F, Altavilla D, Calapai G, DiRosa M, Caputi AP. Role of tumor necrosis factor-α in acute hypovolemic hemorrhagic shock in rats. Am J Physiol. 1994;266(Heart Circ Physiol 35):H1512-H1515.
8. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Am J Int Med. 1984;100:483-490.
9. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest. 1986;78:259-270.
10. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest. 1985;76:1539-1553.
11. Calandra T, Baumgartner JD, Grau MM, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, for the Swiss-Dutch J5 Immunoglobulin Study Group. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis. 1990; 161:982-987.
12. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
13. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321: 280-287.
14. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 1993; 92:2303-2312.
15. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
16. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest. 1992;90:389-398.
17. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL, Natanson C. Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol. 1992; 263:H668-H675.
18. Sodums MT, Badke FR, Starling MR, Little WC, O'Rourke RA. Evaluation of left ventricular contractile performance utilizing end-systolic pressure-volume relations in conscious dogs. Circ Res. 1984; 54:731-739.
19. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine, and dopamine. Life Sci. 1977;21:625-636.
20. Freeman GL, Little WC, O'Rourke RA. Influence of heart rate on left ventricular performance in conscious dogs. Circ Res. 1987;61: 455-464.
21. max-end-diastolic volume relation. Am J Physiol. 1987;252(Heart Circ Physiol 21):H933-H940.
22. Freeman GL, Little WC, O'Rourke RA. The effect of vasoactive agents on the left ventricular end-systolic pressure-volume relation in closed-chest dogs. Circulation. 1986;74:1107-1113.
23. Suga H, Nishiura N. Dissociation of end-ejection from end-systole of ventricle. Jpn Heart J. 1981;22:117-125.
24. Kono A, Maughan WL, Sunagawa K, Hamilton K, Sagawa K, Weisfeldt ML. The use of left ventricular end-ejection pressure and peak pressure in the estimation of the end-systolic pressure-volume relation. Circulation. 1984;70:1057-1065.
25. Hartley HO. The modified Gauss-Newton method for the fitting of non-linear regression functions by least squares. Technometrics. 1961;3:269-280.
26. MAX' to pressure-volume relations: a broader view. Circulation. 1988;77:1203-1212.
27. Glower DD, Spratt JA, Snow ND, Kabas JS, Davis JW, Olsen CO, Tyson GS, Rankin JS. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation. 1985;71:994-1009.
28. max-end-diastolic volume relation in closed chest dogs. Circ Res. 1985;56:808-815.
29. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc Natl Acad Sci USA. 1989;86: 6753-6757.
30. Balligand J-L, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 1993;91:2314-2319.
31. Little WC, Freeman GL, O'Rourke RA. Simultaneous determination of left ventricular end-systolic pressure-volume and pressure-dimension relations in closed-chest dogs. Circulation. 1985;71:1301-1308.
32. Bolli R. Mechanism of myocardial 'stunning.' Circulation. 1990;82: 723-738.
33. Figari IS, Mori NA, Palladino MA. Regulation of neutrophil migration and Superoxide production by recombinant tumor necrosis factors -α and -β: comparison to recombinant interferon-γ and interleukin-1α. Blood. 1987;70:979-984.
34. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, Waltersdorph AM. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986;136:4220-4225.
35. Moser R, Schleiffenbaum B, Groscurth P, Fehr J. Interleukin-1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest. 1989;83: 445-455.
36. Entman ML, Youker K, Shappell SB, Siegel C, Rothlein R, Dreyer WJ, Schmalstieg FC, Smith CW. Neutrophil adherence to isolated adult canine myocytes: evidence for a CD18-dependent mechanism. J Clin Invest. 1990;85:1497-1506.
37. Tsujimoto M, Yokota S, Vilcek J, Weissmann G. Tumor necrosis factor provokes Superoxide anion generation from neutrophils. Biochem Biophys Res Commun. 1986;137:1094-1100.
38. Nathan CF. Neutrophil activation on biological surfaces: massive secretion of hydrogen peroxide in response to products of macrophages and lymphocytes. J Clin Invest. 1987;80:1550-1560.
39. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-142.
40. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol. 1992;105:575-580.
41. Brady AJ, Poole-Wilson PA, Harding SE, Warren JB. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol. 1992;263:H1963-H1966.
42. Little WC, Cheng C-P, Peterson T, Vinten-Johansen J. Response of the left ventricular end-systolic pressure-volume relation in conscious dogs to a wide range of contractile states. Circulation. 1988; 78:736-745.
43. Smith SC, Allen PM. Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res. 1992;70:856-863.
44. Arbustini E, Grasso M, Diegoli M, Bramerio M, Foglieni AS, Albertario M, Matinelli L, Gavazzi A, Goggi C, Campana C, Vigano M. Expression of tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am J Pathol. 1991;139:709-715.
45. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;223:236-241.